Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01281150 · ClinicalTrials.gov registry record · Phase 1

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
3
Study locations

NCT01281150 is a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01281150, a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Carcinoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
3
Study locations

Study Summary

This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving veliparib with carboplatin and paclitaxel may work better in treating patients with solid tumors.

Conditions Studied

Stage IV Breast Cancer Recurrent Breast Carcinoma HER2/Neu Negative Stage IIIB Breast Cancer Stage IIIC Breast Cancer Estrogen Receptor Negative Progesterone Receptor Negative Estrogen Receptor Positive Adult Solid Neoplasm Male Breast Carcinoma

Interventions

  • DRUG Carboplatin
  • OTHER Laboratory Biomarker Analysis
  • DRUG Paclitaxel
  • OTHER Pharmacological Study
  • DRUG Veliparib

Study Locations (3)

Pennsylvania

  • Penn State Milton S Hershey Medical Center - Hershey
  • UPMC-Magee Womens Hospital - Pittsburgh
  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2011-01
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01281150

The ClinicalTrials.gov registry entry for NCT01281150 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (67% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT01281150 reports 3 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01281150 about?

NCT01281150 is a clinical study titled "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors". This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell ...

What is the current status of trial NCT01281150?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-01.

What conditions does trial NCT01281150 study?

This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Carcinoma, HER2/Neu Negative, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer.

What interventions are being tested in trial NCT01281150?

The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Pharmacological Study (OTHER), Veliparib (DRUG).

Who is sponsoring clinical trial NCT01281150?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01281150 being conducted?

This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Breast Cancer

All registered trials for this condition

Recurrent Breast Carcinoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.